Fig. 4From: Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?Locoregional control (LC), progression-free survival (PFS), overall survival (OS)Back to article page